Ebola: Treatment and Prevention

Name: Ebola: Treatment and Prevention
Uploaded: 2025-05-20
Duration: 5 min 57 s
Description: The lecture Ebola: Treatment and Prevention by Jean-Jacques Muyembe-Tamfum, MD, PhD is from the course Ebola.

by Jean-Jacques Muyembe-Tamfum, MD, PhD

Ask Questions

Take Notes

Download Slides

Report Mistake

Comments

show all Show less

My Notes

show all

Learning Material 2

PDF

Slides Ebola Treatment and Prevention.pdf
PDF

Download Lecture Overview

show all

Report mistake

Transcript

00:00 So the second part is, Ebola treatment . F or more than four decades since the discovery of Ebola in 1976, ebola virus disease has no treatment. But today s ince 2022, thanks to the international collaboration, Ebola virus disease is now curable with monoclonal antibodies, including our molecule called ebanga. Monoclonal antibodies 114 that we developed in our laboratory. So the idea of using monoclonal antibodies started in during the outbreak of kikwit. So for the first time, we used a compassionate, compassionate use of convalescent blood to treat Ebola patients. Seven out of eight patients treated with, with, blood from Ebola convalescent were cured. We isolated monoclonal antibodies from a convalescent of Ebola kikwit, capable of neutralizing the Ebola virus in cell culture and in non-human primates. Monotherapy with monoclonal 114 protected macaque monkeys when administrated up to five days after viral inoculation. In a clinical trial conducted during the Ebola outbreak in DRC in 2018 -2022, we demonstrated that monoclonal antibodies one went for administration was safe and well tolerated at a dose of 50mg per kilo. Treatment with a single human monoclonal antibodies suggests that a simplified therapeutics strategy for Ebola is possible, and so we conducted a clinical trial comparing the safety and the effectiveness of three monoclonal antibodies and one antiviral. The antiviral was Remdesevir and the monoclonal MAb114, Regeneron and ZMapp, and Regeneron and Monoclonal 114 were declared very active to reduce the mortality in treated patients, and these two monoclonal antibodies were approved by FDA as a treatment, specific treatment of Ebola patients, adult like children. Our monoclonal we call ebanga the Congolese molecule. So ebanga was like the dream of my life is now reality thanks to the commitment and the tenacity of Congolese scientists. The close collaboration with NIH United States and the contribution of Congolese patients and survivors under the aegis of WHO. And what is the prevention of ebola virus, ebola virus disease? As I said, for more than four decades since the discovery in 1976. Ebola virus disease has no vaccine. Today, thanks to the international collaboration, the Ebola virus disease is preventable with two approved vaccine, the Merck rVSV-Zebov -GP vaccine, called ERVEBO, is used for ring vaccination of contacts of contacts. The second is the Johnson and Johnson vaccine that is used for the general population to obtain the herd immunity in the population. To conclude, we have now for Ebola outbreak. We have treatment and we have vaccine to fight against Ebola outbreak in Africa and in the world.

About the Lecture

The lecture Ebola: Treatment and Prevention by Jean-Jacques Muyembe-Tamfum, MD, PhD is from the course Ebola.

Included Quiz Questions

What was the breakthrough that led to the development of monoclonal antibody therapy for Ebola?

Compassionate use of convalescent blood during the Kikwit outbreak, where 7 out of 8 patients were cured
Discovery of antiviral compounds that could inhibit Ebola replication in laboratory studies
Development of synthetic antibodies created through computer modeling techniques
Isolation of protective proteins from fruit bat reservoirs of the Ebola virus
Analysis of blood samples from healthcare workers who survived Ebola infection

Which monoclonal antibodies were declared most effective and approved by the FDA for Ebola treatment?

Regeneron and monoclonal 114 (ebanga) were approved after demonstrating significant mortality reduction
ZMapp and remdesivir were the first combination therapy approved for clinical use
Convalescent plasma and immunoglobulin preparations from survivors
Synthetic antibodies combined with interferon-based antiviral medications
Monoclonal 228 and favipiravir combination therapy for severe cases

What are the two main vaccination approaches now available for Ebola prevention?

Ervebo (rVSV-ZEBOV-GP) for ring vaccination of contacts and Johnson & Johnson vaccine for population immunity
Live attenuated virus vaccine for healthcare workers and inactivated vaccine for general population
DNA-based vaccine for emergency use and protein subunit vaccine for routine immunization
Viral vector vaccine for adults and conjugate vaccine for pediatric populations
Recombinant vaccine for outbreak response and mRNA vaccine for preventive campaigns

Author of lecture Ebola: Treatment and Prevention

Jean-Jacques Muyembe-Tamfum, MD, PhD

Customer reviews

(1)
5,0 of 5 stars

5 Stars		5
4 Stars		0
3 Stars		0
2 Stars		0
1 Star		0

Playlist

Show Playlist

Hide Playlist